Hospital
Trustees of Mease Hospital INC
Trustees of Mease Hospital INC was paid $9.19M by Medicaid between Jan 2018 and Dec 2024, across 180 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoTRUSTEES OF MEASE HOSPITAL INC
CLEARWATER, FL 33761
CLEARWATER, FL 33761
33aNPI1265419907assigned 12/23/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.19M
24GClaims393,593
24DCodes billed180
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#56 of 163
Median peer was paid$4.77M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,508 | $707K | |
| 2019 | 85,450 | $1.34M | |
| 2020 | 70,806 | $1.10M | |
| 2021 | 88,389 | $1.78M | |
| 2022 | 77,005 | $2.23M | |
| 2023 | 28,122 | $1.36M | |
| 2024incomplete | 9,313 | $675K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 19,027 | 17,274 | $2.03M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 22,800 | 19,108 | $1.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 10,612 | 8,103 | $660K |
| 80053 | Comprehensive metabolic panel | 6.6% | 16,029 | 11,914 | $606K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 5,639 | 4,294 | $402K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 2,927 | 2,434 | $335K |
| 36415 | Collection of venous blood by venipuncture | 3.5% | 28,440 | 18,590 | $318K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.0% | 5,804 | 5,446 | $273K |
| 76819 | Fetal biophysical profile; without non-stress testing | 2.8% | 2,403 | 1,325 | $257K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.1% | 4,868 | 3,871 | $195K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 3,174 | 2,665 | $159K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 1,672 | 1,526 | $140K |
168 more codes
| J7050 | Infusion, normal saline solution, 250 cc | 1.5% | 1,139 | $137K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.5% | 3,044 | $136K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 4,235 | $135K |
| 59025 | Fetal non-stress test | 1.3% | 2,454 | $122K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,382 | $112K |
| G0378 | Hospital observation service, per hour | 1.2% | 12,025 | $110K |
| 81003 | 1.1% | 13,932 | $104K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 1,277 | $102K |
| 82948 | 1.1% | 9,510 | $98K | |
| 59899 | <1% | 2,671 | $86K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,941 | $73K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,573 | $70K |
| 87631 | <1% | 1,348 | $57K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,926 | $54K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,026 | $46K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,903 | $44K |
| 80047 | <1% | 9,199 | $36K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,576 | $35K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 524 | $32K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 875 | $31K |
| 84484 | <1% | 11,134 | $28K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,268 | $24K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 200 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,196 | $20K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 533 | $19K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,861 | $18K |
| 84702 | <1% | 1,132 | $18K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,107 | $18K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,293 | $18K |
| 84112 | <1% | 58 | $17K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 279 | $17K |
| 87480 | <1% | 935 | $17K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 556 | $17K |
| 81025 | <1% | 781 | $16K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 175 | $15K |
| 85610 | <1% | 4,883 | $15K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 439 | $15K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,471 | $15K |
| 74018 | <1% | 1,151 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,010 | $13K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 37 | $12K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,413 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,762 | $10K |
| 83735 | <1% | 4,497 | $9K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 143 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,614 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 573 | $7K |
| 96367 | <1% | 267 | $6K | |
| A9270 | Non-covered item or service | <1% | 3,385 | $6K |
| 85027 | <1% | 2,616 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 354 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 828 | $6K |
| 83880 | <1% | 4,933 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 668 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,307 | $5K |
| 82330 | <1% | 7,809 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 972 | $5K |
| 72100 | <1% | 587 | $5K | |
| 70486 | <1% | 58 | $5K | |
| 73610 | <1% | 208 | $4K | |
| 85730 | <1% | 1,362 | $4K | |
| 93971 | <1% | 310 | $4K | |
| 95811 | <1% | 14 | $4K | |
| J3490 | Unclassified drugs | <1% | 156 | $4K |
| C1769 | Guide wire | <1% | 493 | $4K |
| 84156 | <1% | 601 | $4K | |
| 73562 | <1% | 545 | $4K | |
| 73030 | <1% | 202 | $4K | |
| 87070 | <1% | 220 | $4K | |
| 73630 | <1% | 275 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,297 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 52 | $4K |
| 0100U | <1% | 273 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 42 | $3K |
| C1729 | Catheter, drainage | <1% | 43 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 99 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,648 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 148 | $3K |
| 97162 | <1% | 124 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,327 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,067 | $3K |
| 84703 | <1% | 5,082 | $3K | |
| 84145 | <1% | 1,960 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,970 | $3K |
| 83690 | <1% | 4,944 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 360 | $2K |
| 76801 | <1% | 853 | $2K | |
| 87040 | <1% | 2,612 | $2K | |
| 84100 | <1% | 461 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,061 | $2K |
| 83605 | <1% | 2,171 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 977 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 42 | $2K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 489 | $2K |
| 85380 | <1% | 939 | $2K | |
| 81001 | <1% | 450 | $1K | |
| 80061 | Lipid panel | <1% | 1,018 | $1K |
| 72040 | <1% | 15 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 106 | $1K |
| 86850 | <1% | 1,303 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 60 | $1K |
| 76770 | <1% | 32 | $1K | |
| 87186 | <1% | 1,280 | $851.54 | |
| 87641 | <1% | 254 | $806.75 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 122 | $793.82 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 55 | $793.82 |
| 97161 | <1% | 17 | $785.72 | |
| 86900 | <1% | 1,471 | $777.87 | |
| 73080 | <1% | 17 | $754.55 | |
| 93970 | <1% | 29 | $737.79 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 18 | $736.87 |
| 87077 | <1% | 1,582 | $730.43 | |
| 86140 | <1% | 1,462 | $697.13 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 336 | $696.32 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,336 | $696.08 |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $567.88 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 48 | $536.71 |
| 73130 | <1% | 53 | $535.41 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,065 | $511.48 |
| 36591 | <1% | 72 | $395.77 | |
| 87205 | <1% | 368 | $340.25 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 172 | $319.58 |
| 73110 | <1% | 14 | $297.12 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 972 | $258.21 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 678 | $252.13 |
| 82077 | <1% | 62 | $249.50 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 30 | $231.10 |
| 80076 | <1% | 115 | $227.79 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 668 | $209.04 |
| 82550 | <1% | 357 | $146.96 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 559 | $139.56 |
| 87581 | <1% | 557 | $139.56 | |
| 87486 | <1% | 557 | $139.56 | |
| 87660 | <1% | 922 | $113.08 | |
| 86901 | <1% | 1,474 | $103.76 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 106 | $92.57 |
| 87510 | <1% | 921 | $90.66 | |
| 85652 | <1% | 648 | $88.76 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 16 | $61.15 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 929 | $48.11 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 262 | $42.90 |
| 82570 | <1% | 277 | $37.35 | |
| 72050 | <1% | 21 | $37.31 | |
| 87400 | <1% | 21 | $30.96 | |
| 82607 | <1% | 14 | $11.72 | |
| 84550 | <1% | 64 | $8.44 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 91 | $0.00 |
| 96417 | 0% | 19 | $0.00 | |
| 82805 | 0% | 51 | $0.00 | |
| 29125 | 0% | 69 | $0.00 | |
| 90715 | 0% | 31 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 19 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 76 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 128 | $0.00 |
| 12011 | 0% | 16 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 20 | $0.00 |
| 87506 | 0% | 13 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 52 | $0.00 |
| 87640 | 0% | 14 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 48 | $0.00 |
| 83615 | 0% | 43 | $0.00 | |
| 82728 | 0% | 125 | $0.00 | |
| 72072 | 0% | 13 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 17 | $0.00 |
| 86308 | 0% | 29 | $0.00 | |
| 88342 | 0% | 13 | $0.00 | |
| 72170 | 0% | 16 | $0.00 | |
| 90686 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREMONTI, CARL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Morton Plant Hospital Association INC | New Port Richey, FL | $7.34M |
| Trustees of Mease Hospital INC | Dunedin, FL | $2.90M |
| Behavioral Health Management Services, INC. | Tampa, FL | $1.18M |
| Behavioral Health Management Services, INC. | Clearwater, FL | $698K |
| Morton Plant Hospital Association, INC | Belleair, FL | $582.59 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.